Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 9/21/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. David B. Karpf MD

Wrong Dr. David B. Karpf MD?

Adj. Clinical Professor of Endocr...

Stanford University School of Medicine
Phone: (650) ***-****  
Email: d***@***.edu
Local Address:  San Francisco , California , United States
Stanford University
3145 Porter Dr
Palo Alto , California 94304
United States

Company Description: The Stanford Technology Ventures Program is dedicated to accelerating high-technology entrepreneurship education and creating scholarly research on technology-based...   more

Employment History


  • M.D.
  • MD
  • B.A. , Psychology and Biology
    University of California , Berkeley
  • M.D. degree
    University of California , San Diego
68 Total References
Web References
In The News, 4 June 2008 [cached]
Dr. David B. Karpf, Chief Medical Officer of Metabolex and Clinical Associate Professor of Medicine at Stanford University School of Medicine, stated that to have a drug that addresses insulin resistance without causing the typically observed side effects of weight gain and edema, which should also predict a lower risk of congestive heart failure, would be a significant advance in the treatment of this common and often debilitating disease.
ViroBay, 21 Nov 2014 [cached]
David B. Karpf MD Chief Medical Officer
David B. Karpf MD Chief Medical Officer
David B. Karpf, M.D. has served as our Chief Medical Officer since October 2011. From December 2010 to October 2011, Dr. Karpf served as a life sciences consultant. From January 2004 to December 2010, Dr. Karpf served as Chief Medical Officer and Vice President of Clinical Affairs at Metabolex, Inc., now CymaBay Therapeutics, Inc., where he oversaw the development of clinical programs in various diseases, including type 2 diabetes, gout and dyslipdemia. From May 2001 to January 2004, Dr. Karpf served as Executive Director of Clinical Research and Regulatory Affairs at Geron Corporation, or Geron, a clinical stage biopharmaceutical company, where he oversaw early clinical programs in cancer and regenerative medicine. From May 2000 to May 2001, Dr. Karpf served as Vice President, Clinical and Regulatory Affairs at Calydon, Inc., a company that developed oncolytic virus cancer treatments, which was acquired by Cell Genesis, Inc. in September 2001. From October 1996 to May 2000, Dr. Karpf served as Executive Director of Clinical Research at Roche, where he was responsible for clinical development activities in endocrinology and metabolic bone disease. From August 1991 to December 1996, Dr. Karpf served as Director of Clinical Research at Merck Research Laboratories, where he played a pivotal role in the successful New Drug Application and launch of Fosamax™. Dr. Karpf has also held several academic positions and is currently an adjunct clinical professor of endocrinology at Stanford University School of Medicine. Dr. Karpf received a B.A. in Psychology and Biology from University of California, Berkeley and an M.D. from University of California, San Diego. He completed a residency in Internal Medicine and a fellowship in Endocrinology, Diabetes and Metabolism at University of California, Los Angeles School of Medicine and Cedars-Sinai Medical Center, and a post-doctoral fellowship in the Endocrine Unit at University of California, San Francisco School of Medicine.
Metabolex, Inc., 21 July 2010 [cached]
David B. Karpf
David B. Karpf, M.D. Chief Medical Officer
Dr. Karpf joined Metabolex in 2004 as Chief Medical Officer and Vice President, Clinical and Regulatory Affairs. He previously was at Geron Corporation, where he served as executive medical director, clinical and regulatory affairs from 2001. Prior to Geron, Dr. Karpf was vice president, clinical and regulatory affairs at Calydon, Inc. and executive director of clinical research at Roche Global Development in Palo Alto. From 1991 to 1996, Dr. Karpf was director of clinical research at Merck Research Laboratories in Rahway, New Jersey. Dr. Karpf is currently a clinical professor with the Stanford University School of Medicine. He received his M.D. degree from University of California, San Diego.
Calydon - News, 8 June 2000 [cached]
David Karpf, MD named Calydon's VP, Clinical and Regulatory Affairs
Sunnyvale, CA, June 8, 2000 - Calydon, Inc. is pleased to announce that David B. Karpf, MD has joined as Vice President, Clinical and Regulatory Affairs.Dr. Karpf will be responsible for Calydon's clinical development programs, including the ongoing prostate cancer therapeutics trials.
"David's strengths are in the management of clinical trials and interactions with U.S. and International regulatory agencies.
Dr. Karpf has spent the last nine years in pharmaceutical drug development, most recently at Roche Global Development, where he was Executive Director of Medical Research since 1996.Prior to Roche, he spent five years with Merck Research Laboratories advancing from Associate Director to Senior Director of Clinical Research.He has been responsible for the preparation, management and submission of six NDAs and several INDs.His work experience includes working in the areas of metastatic bone disease and other oncological indications, as well as involvement in multiple licensing evaluations.
Dr. Karpf graduated from the University of California, Berkeley, with degrees in Biology and Psychology before receiving his MD from UC San Diego Medical School.He is board certified in internal medicine and board-eligible in endocrinology.He has researched and published extensively in the area of bone metabolism and has been granted two patents.Additionally, since 1997 he has been Clinical Associate Professor at Stanford University School of Medicine.
Calydon Inc., a privately held company, is engaged in the discovery, development and commercialization of novel virus-based therapeutics for cancer.With its ARCATM technology, the company is able to create tumor-specific viruses that replicate in and kill targeted cancer cells, leaving non-cancer cells unharmed.The company is conducting Phase I/II clinical trials for its prostate cancer therapeutic, CV787, at multiple sites in the United States. (For background information, please visit
[ back ], 31 May 2001 [cached]
MENLO PARK , Calif.-- ( BW HealthWire ) --May 31 , 2001--Geron Corporation ( Nasdaq : GERN ) announced today that David B. Karpf , M.D. , has joined the company as executive medical director for oncology.
We welcome Dr. Karpf into our oncology development group and look forward to his contributions toward advancing our oncology products to the clinic , said Thomas B. Okarma Ph.D. , M.D. , Geron's president and chief executive officer.In his new position , Dr. Karpf will lead the clinical and regulatory activities associated with our four oncology programs : Diagnostics , Telomerase Inhibitors , Oncolytic Virus , and Telemerase Vaccine..
Dr. Karpf brings to Geron extensive experience in clinical product development , including successful interactions with the FDA and international regulatory agencies.Most recently , Dr. Karpf was Vice President , Clinical and Regulatory Affairs at Calydon , Inc. where he was responsible for the development of CV706 and CV787 , replication-selective adenoviruses for the treatment of prostate cancer.Prior to his tenure at Calydon , Dr. Karpf was Senior Director of Clinical Research at Roche Global Development in Palo Alto and was responsible for clinical development activities in metabolic bone disease.From 1991 to 1996 , Dr. Karpf was Director of Clinical Research at Merck Research Laboratories in Rahway , N.J. During his time at Merck he designed , monitored , and completed Phase 2 , 3 and 4 clinical trials on Fosamax ( R ) and played a pivotal role in the successful NDA and launch of this product.His academic experience includes a current appointment as Clinical Associate Professor , Department of Medicine , Stanford University School of Medicine as well as prior faculty appointments in the Department of Medicine , UCSF School of Medicine in San Francisco.
Geron Corporation is a biopharmaceutical company focusing on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine , and research tools for drug discovery.Geron's product development programs are based upon three-patented core technologies : telomerase , human embryonic stem cells and nuclear transfer.
To receive an index and copies of recent press releases , call Geron's News on Demand toll-free fax service , 800/782-3279.Additional information about Geron Corporation can be obtained at
Other People with the name "Karpf":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.